Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Mutational signatures impact the evolution of anti-EGFR antibody resistance in colorectal cancer.

Nature ecology & evolution - 1 Jul 2021

Woolston Andrew, Barber Louise J, Griffiths Beatrice, Pich Oriol, Lopez-Bigas Nuria, Matthews Nik, Rao Sheela, Watkins David, Chau Ian, Starling Naureen, Cunningham David, Gerlinger Marco

Abstract excerpt

Anti-EGFR antibodies such as cetuximab are active against KRAS/NRAS wild-type colorectal cancers (CRCs), but acquired resistance invariably evolves. It is unknown which mutational mechanisms enable resistance evolution and whether adaptive mutagenesis (a transient cetuximab-induced increase in mutation generation) contributes in patients. Here, we investigate these questions in exome sequencing data from 42...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Immunological
Share to Cancer Genomics and Diagnostics

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cetuximab

Share to Colorectal Cancer Treatments and Studies

Share to Colorectal Neoplasms

Share to Genetic factors in colorectal cancer

Share to Mutation

Source

Open in PubMed Open full text

Identifiers

PMID: 34017094
DOI: 10.1038/s41559-021-01470-8
PMCID: PMC7611134

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mutational signatures impact the evolution of anti-EGFR antibody resistance in colorectal cancer.PMID 34017094Read ↗

Mutational processes impact the evolution of anti-EGFR antibody resistance in colorectal cancerSemantic proximity Read ↗

Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients.Semantic proximity Read ↗

KLF4 p.A472D Mutation Contributes to Acquired Resistance to Cetuximab in Colorectal Cancer.Semantic proximity Read ↗

Circulating Tumor DNA Identifies Diverse Landscape of Acquired Resistance to Anti-Epidermal Growth Factor Receptor Therapy in Metastatic Colorectal Cancer.Semantic proximity Read ↗

Genomic and transcriptomic determinants of therapy resistance and immune landscape evolution during anti-EGFR treatment in colorectal cancerSemantic proximity Read ↗

Genomic and Transcriptomic Determinants of Therapy Resistance and Immune Landscape Evolution during Anti-EGFR Treatment in Colorectal CancerSemantic proximity Read ↗

Genomic characterization of intrinsic and acquired resistance to cetuximab in colorectal cancer patientsSemantic proximity Read ↗

Mutational evolution after chemotherapy-progression in metastatic colorectal cancer revealed by circulating tumor DNA analysis.Semantic proximity Read ↗

Resistance to Anti-EGFR Therapy in Colorectal Cancer: From Heterogeneity to Convergent EvolutionSemantic proximity Read ↗

Dynamic ctDNA-based analysis of drug-resistant gene alterations at RAS/BRAF wild-type metastatic colorectal cancer patients after cetuximab plus chemotherapy as the first-line treatment.Semantic proximity Read ↗

Clonal evolution and expansion associated with therapy resistance and relapse of colorectal cancer.Semantic proximity Read ↗

Dynamic alterations of genome and transcriptome in KRAS G13D mutant CRC PDX model treated with cetuximab.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.